Early-stage IP decisions in life sciences often occur under pressure but carry long-term implications for licensing, valuation, and portfolio flexibility. This article explores how early patent strategy shapes commercialization outcomes.

Designing a patent family strategy in life sciences requires more than prosecution. This article explains how U.S. continuation practice can be structured as patent family architecture, aligned to biotech and pharmaceutical regulatory milestones, valuation strategy, licensing, and commercialization, while strengthening patent portfolio risk mitigation.